Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT
Nico Gagelmann,
Diderik-Jan Eikema,
Simona Iacobelli,
Linda Koster,
Hareth Nahi,
Anne-Marie Stoppa,
Tamás Masszi,
Denis Caillot,
Stig Lenhoff,
Miklos Udvardy,
Charles Crawley,
William Arcese,
Clara Mariette,
Ann Hunter,
Xavier Leleu,
Martin Schipperus,
Michel Delforge,
Pietro Pioltelli,
John A. Snowden,
Maija Itälä-Remes,
Maurizio Musso,
Anja van Biezen,
Laurent Garderet,
Nicolaus Kröger
Affiliations
Nico Gagelmann
Department of Stem Cell Transplantation, University Medical Center Hamburg- Eppendorf, Hamburg, Germany
Diderik-Jan Eikema
EBMT Data Office, Leiden, the Netherlands
Simona Iacobelli
Dipartimento di Biologia, Università degli Study di Roma “Tor Vergata”, Italy
Linda Koster
EBMT Data Office, Leiden, the Netherlands
Hareth Nahi
Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden
Anne-Marie Stoppa
Institut Paoli Calmettes, Marseille, France
Tamás Masszi
St. István and St. László Hospital, Budapest, Hungary
Denis Caillot
Hématologie Clinique, Dijon University Hospital, Dijon, France
Stig Lenhoff
Department of Hematology, Skane University Hospital Lund, Sweden
Miklos Udvardy
Department of Hematology, Bone Marrow Transplant Unit, Debrecen Medical University, Hungary
Charles Crawley
Department of Haematology, Cambridge University Hospitals, UK
William Arcese
University Tor Vergata, Roma, Italy
Clara Mariette
Department of Hematology, Grenoble University Hospital, France
Ann Hunter
Leicester Royal Infirmary, Leicester
Xavier Leleu
Hematology, Hôpital La Mileterie, Poitiers, France
Martin Schipperus
Haga Teaching Hospital, the Hague, the Netherlands
Michel Delforge
Department of Hematology, UZ Leuven, Belgium
Pietro Pioltelli
Hematology, Ospedale San Gerardo ASST Monza- Università degli Studi di Milano Bicocca, Monza, Italy
John A. Snowden
Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
Maija Itälä-Remes
Turku University Hospital, Finland
Maurizio Musso
Division of Hematology, Casa di Cura “La Maddalena”, Palermo, Italy
Anja van Biezen
EBMT Data Office, Leiden, the Netherlands
Laurent Garderet
Hopital St Antoine, Paris, France
Nicolaus Kröger
Department of Stem Cell Transplantation, University Medical Center Hamburg- Eppendorf, Hamburg, Germany
We investigated extramedullary disease in newly diagnosed multiple myeloma patients and its impact on outcome following first-line autologous stem cell transplantation. We identified 3744 adult myeloma patients who received up-front single (n=3391) or tandem transplantation (n=353) between 2005 and 2014 with available data on extramedullary involvement at diagnosis. The overall incidence of extramedullary disease was 18.2% (n=682) and increased per year from 6.5% (2005) to 23.7% (2014). Paraskeletal involvement was found in 543 (14.5%) and extramedullary organ involvement in 139 (3.7%). More patients with extramedullary organ involvement had multiple involved sites (≥2; P
